Trastuzumab duocarmazine

N/A

Report date: 2024/02/05 13:59:14

Base Information

Drug NameTrastuzumab duocarmazine
Drug Alias NameAnti-HER2 ADC SYD985,Trastuzumab vcsecoDUBASYD-985
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > seco-DUBA payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2DNA
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesSynthon Bv
China Registration ClassN/A

Develop Information

Active CompaniesByondis BvMedac Gmbh
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursEndometrial Neoplasms +[4] 
Inactive IndicationsNeoplasm MetastasisUrinary Bladder NeoplasmsOvarian Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A